November 24th 2020
By Tony Hagen
GP2 peptide/G-CSF in HER2-equivocal and -positive breast cancer has shown promise.
November 23rd 2020
Bevacizuamb biosimilar in combination with sintilimab delivered significantly improved overall survival vs sorafenib.
Pfizer aims to begin marketing Nyvepria in the European Union in the first quarter of 2021.
November 20th 2020
Their rituximab biosimilar candidate was advancing in clinical trials for equivalence but represented a business conflict.
November 18th 2020
Jorge Garcia, MS, assistant vice president of the System Oncology Pharmacy Service Line at Baptist Health South Florida, discussed how the pandemic has interrupted oncology care for patients and affected the utilization of pegfilgrastim biosimilars.
November 17th 2020
Despite a rocky power transition at the federal level, the compass heading for biosimilars is unchanged, said policy expert Molly Burich.
November 16th 2020
The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.
November 15th 2020
Kathy Oubre, MS, chief operating officer at the Pontchartrain Cancer Center in Louisiana, discusses the value of biosimilars.
November 12th 2020
By Skylar Jeremias
Alvotech and Cipla have joined forces to bring biosimilars to treat oncology and autoimmune diseases to South Africa.
Prestige Biopharma and Teva Israel join forces to bring a trastuzumab biosimilar to the Israeli market.
